␤ 2 -Adrenergic and chemokine receptor antagonists delay the onset and reduce the severity of joint injury in rheumatoid arthritis. ␤ 2 -Adrenergic and chemokine receptors belong to the G-protein-coupled receptor family whose responsiveness is turned off by the G-protein-coupled receptor kinase family (GRK-1 to 6). GRKs phosphorylate receptors in an agonist-dependent manner resulting in receptor/G-protein uncoupling via subsequent binding of arrestin proteins. We assessed the activity of GRKs in lymphocytes of rheumatoid arthritis (RA) patients by rhodopsin phosphorylation. We found a significant decrease in GRK activity in RA subjects that is mirrored by a decrease in GRK-2 protein expression. Moreover, GRK-6 protein expression is reduced in RA patients whereas GRK-5 protein levels were unchanged. In search of an underlying mechanism, we demonstrated that proinflammatory cytokines induce a decrease in GRK-2 protein levels in leukocytes from healthy donors. Since proinflammatory cytokines are abundantly expressed in RA, it may provide an explanation for the decrease in GRK-2 expression and activity in patients. No changes in ␤ 2 -adrenergic receptor number and K d were detected. However, RA patients showed a significantly increased cAMP production and inhibition of TNF-␣ production by ␤ 2 -adrenergic stimulation, suggesting that reduced GRK activity is associated with increased sensitivity to ␤ 2 -adrenergic activation.-Lombardi, M. S., Kavelaars, A., Schedlowski, M., Bijlsma, J. W. J., Okihara, K. L., Van de Pol, M., Ochsmann, S., Pawlak, C., Schmidt, R. E., Heijnen, C. J. Decreased expression and activity of G-proteincoupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J. 13, 715-725 (1999) 
Rheumatoid arthritis (RA)
2 is a chronic inflammatory disease of the synovial joints characterized by leukocyte invasion and synoviocyte activation, leading to cartilage and bone destruction. Although its pathogenesis is poorly understood, multiple factors including genetic contribution of HLA class II antigens, impaired control of virus and/or bacterial infections, and altered sex hormone status have been mentioned to increase susceptibility to develop RA (1) . Moreover, an increasing number of investigations suggest a pivotal role in the pathology of RA for the proinflammatory cytokines due to their biological functions as mediators of inflammation, cell growth, and activation (2) . In recent years an involvement of the nervous system in the pathogenesis of RA has also become evident. Treatment of rats with ␤ 2 -adrenergic receptor antagonists, before and during the induction of adjuvant arthritis, delays the onset and reduces the severity of joint injury (3) . The proinflammatory effects of the sympathetic nervous system in RA have previously been suggested from clinical observations that 1) the distribution of synovitis is symmetric (4), 2) joints in the paretic side of hemiplegic or poliomyelitic patients who later de-velop RA are spared from the inflammatory process (5) , and 3) the onset and exacerbation of the disease is often preceded by psychological trauma or stress (6) . The latter is not surprising as lymphoid tissues are densely innervated with postganglionic noradrenergic and peptidergic neurons (7) , suggesting that sympathetic innervation may play an important role in the inflammatory response.
Chemokines may also play a role in arthritis. These proteins are known to mediate the chemotaxis and activation of leukocytes (8) . In two murine models of arthritis (MRL-lpr and DBA/1), it has recently been shown that administration of receptor antagonists of MCP-1 (monocyte chemoattractant protein-1) and RANTES (regulated on activation normal T cell expressed and secreted), respectively can have beneficial effects on the disease process (9, 10) . The latter data strongly suggest that these chemokines and their receptors play an important role in this chronic inflammatory disease by initiating and maintaining the local inflammatory process through recruitment of monocytes and lymphocytes in the joints (2) .
␤ 2 -Adrenergic and chemokine receptors belong to the G-protein-coupled receptor (GPCR) family whose responsiveness is actively 'turned off' by members of the G-protein-coupled receptor kinase (GRK) family consisting of six known subtypes, GRK-1 to -6 (11). These kinases are responsible for the rapid loss of receptor responsiveness despite continuous presence of the agonist, a process known as homologous desensitization. GRKs phosphorylate serine/threonine residues in the carboxyl-tail and/or intracellular loops of receptors in an agonist-dependent manner. The phosphorylated form of the receptors act as substrates for a class of inhibitory proteins called ␤-arrestins, which sterically inhibit further receptor/ G-protein coupling (12) . Uncoupled receptors are subsequently removed from the plasma membrane. Recent studies also suggest that both GRK and arrestins play a key role in this sequestration process (13, 14) . Receptor substrates for GRKs identified so far are involved in a wide variety of functions, ranging from neurotransmission to immune responses (i.e., ␤ 2 -and ␣ 2 adrenergic receptors, muscarinic cholinergic receptors, substance P receptor, CCR2B and CCR5 chemokine receptors, fMLP receptor, etc.), and transduce signals through various intracellular second messengers (11) .
Among the six known GRKs, four (GRK-2, GRK-3, GRK-5, and GRK-6) are highly expressed in peripheral blood leukocytes (PBL) and in some myeloid and lymphoid cell lines (15) (16) (17) . Alterations in GRK activity have been demonstrated in T cell activation (16) as well as in human diseases like hypertension (18) and heart failure (19) . As the use of antagonists of GPCRs has been proven to produce beneficial effects on the onset and the severity of the arthritis, we wondered whether in RA patients the proinflammatory signal pathways mediated through some Gprotein-coupled receptors are less efficiently turned off by the GRK/␤-arrestin desensitization machinery. Therefore, we have assessed GRK activity and expression in human peripheral blood mononuclear cells (PBMC) from RA patients and healthy controls.
MATERIALS AND METHODS

Subject protocol
Patients were selected according to the American Rheumatism Association 1987 classification criteria (20) . The group consisted of 16 patients with RA (12 female and 4 male) who ranged in age from 23 to 76 years, with a mean age of 48.6 (Ϯ 15). 15 patients were taking nonsteroidal antiinflammatory drugs (NSAIDs) and 1 patient was untreated. In addition, patients were taking disease modifying antirheumatic drugs and/or glucocorticoids (3 hydroxychloroquine, 3 oral methotrexate, 3 hydroxychloroquine ϩ oral methotrexate, 1 hydroxychloroquine ϩ prednisone, 1 hydroxychloroquine ϩ prednisone ϩ oral methotrexate, 1 cortisone, 2 Azulfidine, 1 Azulfidine ϩ methotrexate). Sex and age-matched healthy controls were recruited. Controls were free of chronic pain, cardiovascular complaints, or other chronic inflammatory diseases.
Sample preparation
PBMC were isolated from heparin anticoagulated whole blood by Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) density gradients (21) . For preparation of cytosolic fractions, PBMC were lysed in ice-cold lysis buffer (10 mM Tris, 5 mM EDTA, 7.5 mM MgCl 2 , 0.1 mM PMSF, 10 g/ml leupeptin, 5 g/ml pepstatin, 10 g/ml benzamidine, at pH 7.4), using a polytron tissue disrupter (Janke and Kundel, Staufen, Germany) at low speed for 40 s on ice. Unbroken cells and nuclei were pelleted by centrifugation (800 ϫ g for 5 min) and discarded. The supernatant was then centrifuged (48,000 ϫ g for 20 min at 4°C) to separate plasma membrane from the cytosol. The latter was centrifuged at 300,000 ϫ g for 30 min at 4°C. The supernatant was collected and frozen in liquid nitrogen. Membrane preparation was washed once in cell lysis buffer and recentrifuged at 48,000 ϫ g for 20 min at 4°C; the resultant membrane pellet was resuspended in cell lysis buffer and sonicated for 5 s before protein determination. In addition to assay membrane-associated GRK activity, membranes were washed once in cell lysis buffer, centrifuged at 48,000 ϫ g for 20 min at 4°C, and the resultant membrane pellet was resuspended in cell lysis buffer with 250 mM NaCl (to detach membrane-bound GRKs) (22) . The suspension was sonicated briefly, incubated for 30 min at 4°C and centrifuged as above. Membrane-detached proteins (2-5 g) were used in the phosphorylation assay. Protein concentration was determined with a Bio-Rad protein assay reagent, using bovine serum albumin as standard. quent treatment with 5M urea to inactivate endogenous rhodopsin kinase activity. The resulting preparation contained ϳ 95% rhodopsin (23) and showed negligible endogenous kinase activity.
Four GRK subtypes are highly expressed in PBL and their ability to phosphorylate ROS, when transiently expressed in COS7 cells, shows the following relative order of potency: GRK-2 Ͼ Ͼ GRK-3 ϭ GRK-5 Ͼ Ͼ GRK-6. In this paper, therefore, we refer to the ROS phosphorylation assay as GRK activity, although it mainly measures GRK-2 activity (16) .
GRK-dependent phosphorylation was determined by incubating 50 g of cytosolic protein with ϳ 300 pmol of rhodopsin in a buffer containing 65 M [ ␥-
33 P] ATP (2-5 cpm/fmol, Amersham, Buckinghamshire, U.K.), 20 mM Tris, 8 mM MgCl 2 , 3 mM EDTA, 5 mM NaF, 12 mM NaCl at pH 7.4 in a final reaction volume of 100 l. The reactions were carried out at 30°C for 30 min in presence (or absence) of light. The incubations were terminated by the addition of 40 l of sodium dodecyl sulfate (SDS) sample buffer (8% SDS, 20% glycerol, 5% ␤-mercaptoethanol, 250 mM Tris-HCl pH 6.8 and 0.003% bromphenol blue). Samples were then electrophoresed on 10% SDS-polyacrylamide gel electrophoresis (PAGE) (24) . After electrophoresis, the gel was stained with Coomassie blue, dried, and phosphorylated rhodopsin was visualized by autoradiography. Bands corresponding to rhodopsin (ϳ 38 kDa) were cut from the gel and quantitated via liquid scintillation spectroscopy. The GRK-dependent phosphorylation was confirmed by adding the protein kinase A inhibitor PKI (1 M, Sigma Chemical Co., St. Louis, Mo.) and heparin (10 g/ml, Leo chemicals, Netherlands) to the reaction and the ability to phosphorylate rhodopsin was determined. Heparin inhibited phosphorylation but PKI did not. All results were confirmed in at least three separate experiments, using cells obtained from different individuals.
Assessment of GRK and arrestin expression
Assessment of GRK and arrestin protein expression was determined by immunoblotting. GRK-2, GRK-5, and GRK-6 protein expression was determined using a 1:200 dilution (in all cases) of a rabbit polyclonal antibodies raised against amino acids 675-689 of human GRK-2, amino acids 571-590 of human GRK-5, and amino acids 525-544 of human GRK6, respectively. All antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, Calif.).
Expression of arrestins was determined using a 1:2,000 dilution of the arrestin mouse monoclonal antibody F4C1, which recognizes the epitope DGVVLVD, identical in human ␤-arrestin 1, arrestin 3 (␤-arrestin 2), and arrestin (25) .
Samples containing 30 g of proteins were suspended in sample buffer (as above) by gentle shaking for 10 -15 min at 37°C and electrophoresed on 10% SDS-PAGE. Proteins were transferred to presoaked nitrocellulose membranes (Hybond-C, Amersham) by electroblotting at 100 V for 1 h Efficiency of transfer was verified by Ponceau red staining. Membranes were soaked in a blocking buffer solution of 5% non-fat dry milk in TTBS (10 mM Tris-HCl pH 7.5, 0.9% NaCl, 0.05% Tween 20) for 1 h (2 h in the case of arrestin) at room temperature, then incubated with antibodies (anti GRKs or arrestin) diluted in TTBS for 1 h (2 h in the case of arrestin) at room temperature. Membranes were washed three times with Tris-buffered saline and incubated for 1 h at room temperature with either peroxidase-conjugated donkey anti-rabbit IgG (Amersham) at 1:10,000 dilution (for all GRKs antibodies) or peroxidase-conjugated sheep anti-mouse IgG (Boehringer Mannheim GmbH, Germany) at 1:10,000 dilution (for arrestin antibody). Immunoreactivity was detected with an enhanced chemiluminescence detection system (ECL, Amersham Int.) and bands were visualized after exposing blots to X-ray film. In some cases the same membrane was used for subsequent reprobing with specific antibodies after being stripped by incubating for 20 min in 0.1M glycine pH 2.9 at room temperature. Autoradiographs were scanned using a GS-700 Imaging Densitometer (Bio-Rad Laboratories, Hercules, Calif.). All results were confirmed in at least three separate experiments, using cells obtained from different individuals.
Northern blot analysis
Total RNA was isolated from PBMC using RNAzol (CAMPRO Sci., Veenendaal, Netherlands). The integrity and purity of the RNA was assessed by gel electrophoresis and ultraviolet absorbance ratio; the sample was rejected if the ratio was Ͻ 1.6 or if visual inspection of the photographed gel suggested degradation. Then 15 g/lane were fractionated on a 1% agarose-formaldehyde gel, transferred to a Hybond Nϩ membrane (Amersham), and immobilized with a Stratalinker UV light source. Northern blot analysis was performed using the random primed cDNA fragment (bp 955-2007) of GRK-2 as probe (15) . Hybridization was for 20 h at 42°C in 50% formamide, 10% dextran sulfate, 1% SDS, 5.8% NaCl, and denatured herring sperm DNA (100 g/ml). The blot was then washed twice in 2X SSC for 5 min, twice in 2X SSC/1% SDS at 60°C for 15 min, once in 0.2X SSC/0.1% SDS at 42°C for 15 min, then rinsed briefly in 0.1X SSC at room temperature and subjected to autoradiography at Ϫ80°C for 24 -72 h. GRK-6 mRNA expression was determined on the same filter, after being stripped with boiling 0.5% SDS, using a random primed cDNA fragment (bp 1114 -2030) of GRK-6 (26). Hybridization and washings were performed as described above. All results were confirmed in at least two separate experiments, using cells obtained from different individuals. 125 I]ICYP (range 10 -150 pM) at 37°C for 30 min Nonspecific binding was determined under the same conditions in the presence of 1 mM (-) propranolol (Sigma Chemical Co.). After the incubation, 100 l of the mixture was pipetted in to Scatchard tubes (Sarstedt), containing 150 l of an oil-phthalate mixture (20% oil, 80% phthalate). Subsequently, the tubes were centrifuged for 90 s at 13,000 ϫ g in a Microfuge and the part of the tube containing the cell pellet was cut off. Both the radioactivity bound to the cells as well as the amount of free label was determined in a gamma counter.
TNF-␣ production
Tumor necrosis factor alpha (TNF-␣) production was induced by culturing 100 l of diluted whole blood (1:10 in RPMI 1640 supplemented with antibiotics) with 50 l of lipopolysaccharide (LPS) (Escherichia coli, Difco, Detroit, MI) in a final concentration of 2 ng/ml and 50 l of medium or the ␤ 2 -adrenergic receptor agonist terbutaline (Sigma Chemical Co.) in the concentrations 0 -500 nM. After 18 h of culture at 37°C, supernatants were harvested and stored at Ϫ80°C until analysis. TNF-␣ levels in the supernatants were determined by ELISA (Pelikine, CLB, Amsterdam, The Netherlands).
cAMP accumulation PBMC were isolated as described above and resuspended in RPMI containing 20 mM HEPES at a density of 10 ϫ 10 6 cells/ml. Cell viability, as assessed by trypan blue exclusion, was higher than 90% in all samples. The stimulation of cAMP accumulation (27) was performed (in duplicate) by adding 0.1 ml of cell suspension to 0.9 ml DMEM (prewarmed at 37°C) containing 1 mM isobutyl-methylxanthine (IBMX, to inhibit phosphodiesterase activity) and 1 M (-) isoproterenol (Sigma, Chemical Co.) for different times or no agonist (basal) at 37°C. Isoproterenol was protected against oxidation in these incubations by adding 20 g/ml each of superoxide dismutase and catalase (both from Sigma). The reactions were terminated by centrifugation for 20 s. The supernatant was quickly removed and the pellet was resuspended in 250 l Tris-EDTA (50 mM) buffer at pH 7.5. The samples were placed in a boiling water bath for 5 min, then frozen. After thawing, samples were sonicated and the protein flocculate was pelleted by centrifugation. Aliquots (50 l) of the resulting supernatants were assayed using a cAMP[
125 I] scintillation proximity assay system kit (Amersham Pharmacia Biotech) following manufacturer's instructions.
Cytokine treatment of PBMC
PBMCs from healthy donors were isolated as described above and resuspended in RPMI-1640 culture medium (Life Technologies, Inc. Life Technologies, Inc., Grand Island, N.Y.) supplemented with 5% fetal calf serum (Life Technologies, Inc.), 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. PBMCs (2 ϫ 10 6 /ml) were then cultured for 6, 24, or 48 h in the absence or presence of 10 ng/ml of IL-6 (PreproTech, Inc., Rocky Hill, N.J.) or 20 ng/ml of rhIFN-␥ (recombinant human interferon-␥, R&D Systems, Minneapolis, Minn.) in 5% CO 2 at 37°C. Cells were then harvested and tested for viability by trypan blue exclusion. In all samples viability was higher than 90%. Cytosolic fractions were isolated and analyzed by Western blot, as described above. All results were confirmed in at least two separate experiments, using cells obtained from different individuals.
Statistical analysis
Data are expressed as a mean value Ϯ se. Specific measurements were compared using the Student's t test for unpaired (unless otherwise stated) data. Data for inhibition of TNF-␣ production and cAMP accumulation were analyzed using two-way analysis of variance (ANOVA). A value of PϽ0.05 on a two-tailed test was used as a minimum level of significance.
RESULTS
GRK activity in human PBMC
To assess GRK activity in PBMC cytosolic fractions, ROS were used as a specific substrate resulting in a light (agonist) -dependent phosphorylation of the correspondent ϳ38 kDa band (Fig. 1A) . No such phosphorylation was observed when the cytosolic fraction was omitted from the ROS incubation, indicating the absence of rhodopsin kinase (GRK-1) in the ROS preparation (data not shown). The lightdependent ROS phosphorylation was completely inhibited by the addition of heparin (10 g/ml) and was not blocked by 1 M protein kinase A inhibitor PKI (data not shown).
In cytosolic fractions of PBMC from RA patients, GRK activity was significantly decreased (109 Ϯ 9 fmol ⅐ min Ϫ1 ⅐ mg cytosolic protein Ϫ1 , PϽ0.001) as compared with GRK activity in samples from healthy donors (216 Ϯ 14 fmol ⅐ min Ϫ1 ⅐ mg cytosolic protein Ϫ1 ) (Fig. 1C) . Although GRKs are essentially cytosolic proteins, a significant amount of kinase activity is associated with the plasma membrane (16, 28) . To rule out the possibility that the decrease in GRK activity found in PBMC from RA patients was simply due to GRKs translocation from cytosol to membrane fractions, we also assessed membrane-associated kinase activity. We found a similar decrease (46 Ϯ 6%) in membrane-associated GRK activity in PBMC from RA patients in comparison to healthy donors (Fig. 1B) .
GRK-2 protein expression
To determine whether the decrease observed in GRK-mediated phosphorylation of ROS in PBMC from RA patients was associated with a decrease in immunodetectable GRK-2 protein, we performed quantitative Western blotting analysis. The anti-GRK-2 antibody recognizes a protein of an apparent molecular mass of ϳ 80 kDa that comigrates with recombinant GRK-2 protein (Fig. 2A) . Immunodetectable GRK-2 ( Fig. 2B ) was significantly reduced in cytosolic fractions from PBMC of RA subjects (191 Ϯ 10 ng/mg cytosolic protein, PϽ0.001) compared with healthy donors (453 Ϯ 24 ng/mg cytosolic protein).
GRK-5 and GRK-6 protein expression
We assessed levels of immunodetectable GRK-5 and GRK-6 by Western blotting to determine whether the decrease observed in GRK activity was due to a selective decrease in GRK-2 expression or to a more general decrease in the expression of other GRKs. Western blotting of immunodetectable GRK-5 (Fig.  3A) showed that there were no significant differences (RA: 91 Ϯ 4.5% of expression in healthy donors) in cytosolic fractions of PBMC from RA patients when compared with healthy controls (Fig.  3B) . Similar results were obtained with membraneextracted fractions (29) (data not shown).
In PBMC from RA patients and healthy controls, two GRK6 immunoreactive bands of ϳ 65 and ϳ 67 kDa were detected in cytosolic fractions (Fig. 4A) . We found a decrease in GRK-6 protein levels in cytosolic fractions from PBMC from RA patients compared with healthy controls. When both bands of the 65/67 kDa protein doublet were analyzed by densitometry, the net decrease observed in RA subjects was ϳ 66% (Fig. 4B, PϽ0.001) . Moreover, when the bands were analyzed separately, the 65 kDa bands showed a ϳ 90% decrease in PBMC from RA subjects while the decrease of the 67 kDa bands was ϳ 53% when compared with healthy controls. A similar decrease (ϳ 40%) in RA patients compared with healthy donors was observed in membrane fractions (Fig. 4C) .
Assessment of ␤-arrestin expression by immunodetection
We assessed whether the decrease in GRK-2 and GRK-6 protein was associated with a change in ␤-arrestin immunodetectable levels. The anti-␤-arrestin antibody used for Western blot recognizes two proteins of ϳ 55 and ϳ 52 kDa corresponding to ␤-arrestin-1 and arrestin 3, respectively (Fig. 5A) . Figure 5B shows that immunodetectable levels of the arrestins were not significantly different in cytosolic samples of PBMC from RA patients in comparison to healthy controls (94 Ϯ 5%, Pϭ0.25).
Northern blot analysis of GRK-2 and GRK-6
We next determined whether GRK-2 and GRK-6 mRNA expression levels were associated with the decrease observed in protein expression in PBMC from RA patients. GRK-2 mRNA levels (ϳ 3.8 kb transcript) in PBMC from RA patients were not significantly different from that of healthy donors (102 Ϯ 3% of controls) ( Table 1 ). The latter suggests that the decrease in GRK-2 protein is caused by a (nϭ6, 109 Ϯ 9 fmol ⅐ min Ϫ1 ⅐ mg cytosolic protein Ϫ1 ) and HD (nϭ8, 216 Ϯ 14 fmol ⅐ min Ϫ1 ⅐ mg cytosolic protein
Ϫ1
). The data represent the mean Ϯ se ***PϽ0.001. mechanism of posttranscriptional regulation and/or alteration in protein stability. The same gel was stripped and hybridized again with a GRK-6 cDNA probe, which detects two transcripts of ϳ 3 and ϳ2.4 kb, respectively (26) . Recently it has been shown that these two mRNA species can arise from alternative splicing in the 3Ј untranslated region and/or be due to alternative polyadenylation of transcripts from a single gene in human chromosome 5 (30) . We observed a slight decrease of the upper transcript in RA patients (16.5 Ϯ 1.4%, Pϭ0.054) whereas the lower mRNA species is not significantly changed (94 Ϯ 6.5% of healthy donors) ( Table 1) .
Determination of ␤ 2 -adrenergic receptors on PBMC
The density (B max ) and K d of ␤ 2 -adrenergic receptors on PBMC from RA patients (nϭ7) and healthy donors (nϭ8) showed no significant differences between the two groups ( Table 2) .
␤ 2 -Adrenergic receptor function
To investigate whether the reduced GRK activity is associated with an alteration in ␤ 2 -adrenergic receptor function, we tested the ability of the ␤ 2 -adrenergic receptor agonist terbutaline to inhibit the production of TNF-␣ by PBL of RA patients and healthy donors in a dose-dependent manner (31) . For this purpose, whole blood was diluted (1:10 in RPMI 1640) and cultured in the presence of LPS (2 ng/ml) to induce TNF-␣ production and terbutaline in a dose range of 0 -500 nM. The results of Fig. 6A show clearly that the dose-dependent inhibition of TNF-␣ production by terbutaline is significantly increased in RA patients compared with healthy controls (two-way ANOVA, PϽ0.0001). We also studied the kinetics of cAMP accumulation in PBMC from RA patients and healthy donors in the presence of a phosphodiesterase inhibitor (IBMX). Figure 6B shows that the production of cAMP in PBMC from RA patients was significantly increased (two-way ANOVA, PϽ0.001).
Effects of cytokine treatment on GRK-2 protein expression
To investigate a possible mechanism responsible for the GRK-2 down-regulation observed in PBMC from RA patients, we tested whether proinflammatory cytokines, which are known to be increased in RA, can affect GRK-2 protein expression. PBMCs from healthy donors were cultured in the absence or presence of 10 ng/ml of IL-6 or 20 ng/ml of rhIFN-␥ for 6, 24, or 48 h and GRK-2 protein levels were assessed by Western blot analysis. No significant changes in GRK-2 protein were observed for rhIFN-␥-treated cells after 6 h, but after 24 h and 48 h we observed a marked decrease of 57% and 80%, respectively, when compared with the expression of the respective untreated controls, which was considered 100% (Fig. 7A ). An even more pronounced effect was observed in IL-6 treated cells. A decrease of ϳ 40% was already evident after 6 h; after 48 h, the GRK-2 protein was barely detectable (Fig. 7B) .
DISCUSSION
In the present study we demonstrated a significant reduction of GRK activity in PBMC of RA patients compared with healthy donors. The reduction in GRK activity can be attributed to a decreased level of GRK-2 protein expression. Moreover, we observed in both membrane and cytosolic fractions a decrease GRK-6 protein expression in RA patients, whereas GRK-5 protein levels were unchanged. No changes in ␤-arrestin-1 and arrestin-3 immunodetectable levels were observed. Northern blot analysis of GRK-2 and GRK-6 mRNA levels shows no significant differences between RA patients and controls. No changes in ␤ 2 -adrenergic receptor number and K d were detected. However, RA patients showed both a signifi- a mRNA expression in rheumatoid arthritis (RA) patients, quantified by densitometric analysis of autoradiographic films, is expressed as percentage of expression in healthy donors (HD). For GRK-6, the two mRNA species of 3 and 2.4 Kb in size were quantified. Data are means Ϯ se of four individuals per group tested in two independent experiments. NS ϭ not significant. cantly increased cAMP production and inhibition of TNF-␣ production by a ␤ 2 -adrenergic agonist stimulation. Moreover, treatment of PBMC from healthy donors with proinflammatory cytokines like IL-6 and IFN-␥ induces a down-regulation of GRK-2 protein levels.
The possibility that drug treatment of patients is responsible for the observed down-regulation of GRKs in RA patients is very unlikely. We demonstrated in an in vitro model (32) that GRK activity is not altered by NSAIDs (M.S. Lombardi, unpublished observations). Moreover, treatment of PBMC with 1 M dexamethasone for 24 -48 h does not induce changes in GRK activity and GRK-2 protein expression levels (M. S. Lombardi et al., unpublished observations). Fifty percent of our patients received methotrexate. However, we did not observe any difference in GRK activity and expression between patients who did or did not receive this antimetabolite drug. Moreover, it seems unlikely that this interference with cellular metabolism has differential effects on the expression of the various GRK proteins.
The Northern blot analysis of GRK-2 and GRK-6 suggests that the reduction in GRK activity and GRK-2 and GRK-6 protein may be due to changes at the posttranscriptional level and/or on the level of protein stability. Previous sequence analysis has shown that there is a high degree of secondary structure formation at the 5Ј region of GRK-2 mRNA Figure 6 . A) Inhibition of TNF-␣ production by the ␤ 2 -adrenergic receptor agonist terbutaline. Whole blood from rheumatoid arthritis (RA) patients (nϭ16, filled circles) and healthy donors (HD) (nϭ15, unfilled circles) was diluted (1:10 in RPMI 1640) and cultured in the presence of LPS (2 ng/ml) to induce TNF-␣ production and terbutaline in the doses indicated for 18 h at 37°C. Supernatants were harvested and TNF-␣ levels were determined by ELISA. The dose-dependent inhibition of TNF-␣ production by terbutaline is significantly increased in RA patients compared to healthy controls (two-way ANOVA, PϽ0.0001). The data are means Ϯ se. Data are expressed as percent inhibition of TNF-␣ production in the absence of terbutaline. TNF-␣ production in the absence of terbutaline was 498 Ϯ 74 pg/ml for RA patients and 369 Ϯ 68 pg/ml for healthy donors. B) Time course of 1 M (-) isoproterenol stimulated cAMP production in PBMC from rheumatoid arthritis patients (nϭ3, filled circles) and healthy donors (nϭ4, unfilled circles). Data are expressed as percentage of the basal cAMP levels. Basal levels of cAMP were 5.9 Ϯ 1.02 pmol/10 6 cells for RA patients and 11.7 Ϯ 1.09 pmol/10 6 cells for HD. due to a high GC content. This observation suggests an argument for posttranscriptional regulation to occur (33) . Western blot analysis of cytosolic GRK-6 revealed a differential expression of the two immunodetectable bands (a ϳ53% decrease of the 67 kDa bands and a ϳ 90% decrease of the 65 kDa bands in RA subjects compared with healthy donors). The significance of this phenomenon is unclear. However, two GRK-6 splice variants were recently found in the rat. They encode for two isoforms of GRK-6: GRK-6a and GRK-6b, of 576 aa and 589 amino acids, respectively, differing in their COOH-terminal domain (34) . It may be that the observed ϳ 65/67 kDa doublet reflects the homologous human GRK-6 splice variants. Elucidation of the physiological role of the two GRK-6 isoforms and the identification of more specific substrates for GRK-6, which are expected to be distinct from those identified for GRK-2 as suggested by in vitro studies (35) , may provide more insight on this issue. For both kinases, a selective and cell-specific differential expression at both mRNA and protein levels has been recently described in myelomonocytic and lymphoid cells (16, 36) . These data suggest that these kinases play an important role in modulating several G-proteincoupled receptors expressed in immune cells. It has been described that T cells in the peripheral circulation of RA patients are activated due to the inflammatory process (37) . However, the decrease of GRK activity and expression in PBMC of RA patients is apparently not due to already in vivo activated T cells, since activation of PBMC by mitogen or anti-CD3 leads to a clear increase of GRK-2 and GRK-6 activity and expression (16, 36) .
Why do we observe a decrease in GRK activity and GRK-2 and GRK-6 expression? To approach this issue, we investigated whether the proinflammatory cytokines IL-6 and IFN-␥ are able to modulate GRK-2 expression in cells of healthy control donors. We show here for the first time that these cytokines indeed down-regulate the expression of GRK-2 in PBMC from healthy donors. The production of proinflammatory cytokines is known to be increased in RA patients, and the TH1 cytokine IFN-␥ has been shown to play a central role in maintaining the inflammatory process (11) More recently, a role for IL-6 in a murine model of antigen-induced arthritis has been more clearly established (38) . On the basis of our results, we hypothesize that the increased production of proinflammatory cytokines causes the decrease observed in GRK-2 expression and activity in RA. Via this mechanism, cytokines may contribute to enhanced reactivity of PBMC to agonists that signal via G-protein-coupled receptors. In heart failure, a sustained activation of the sympathetic nervous system is associated with an increase of both GRK activity and GRK-2 mRNA (19, 39) . The concept that GRK activity may be related to the degree of sympathetic stimulation in vivo also arises from the observation that an increase of GRK activity occurs in the liver of neonate rats after the transient physiological increase of catecholamines (40) . On the other hand, diminished activity of the autonomic nervous system has recently been demonstrated in both established and recent onset RA patients and associated with decreased sympathetic activity (41) . From this data, we may hypothesize that reduced sympathetic activity could be responsible for the observed reduction in GRK activity and expression in PBMC from RA patients. Whether down-regulation of GRKs may be interpreted as an adaptive response of the adrenergic receptor system remains to be elucidated. It is, however, remarkable that ␤ 2 -adrenergic receptors on PBL from RA patients have an increased signaling capacity when compared with ␤ 2 -adrenergic receptors from healthy individuals and that the production of cAMP in PBMC from RA patients was significantly increased (Fig. 6A, B) . The fact that the number and the K d of ␤ 2 -adrenergic receptors are not significantly different between patients and controls indicates a reduced homologous desensitization consistent with the decreased levels of GRK activity observed in RA patients. Therefore, we suggest that the reduced GRK activity is associated with an increased sensitivity to ␤ 2 -adrenergic stimulation.
The lower GRK activity and expression in RA subjects may also have consequences for the function of other GPCR that play a role in the disease process. The use of several experimental approaches, including reconstitution studies in vitro, receptor mutagenesis, and GRK/␤-arrestin overexpression in some cell lines, have demonstrated that the GRK/␤-arrestin desensitization machinery is involved in the regulation of a large number of GPCR. One example is the substance P (SP) receptor, which is a substrate for GRK-2 and -3 (42) . SP has many proinflammatory effects in vivo and has been demonstrated to play an important role in the pathogenesis of RA. It is significantly increased in the synovial fluid of RA patients (43) and can be released from primary afferent nerve fibers into the joints. If, indeed, the SP receptor signaling system is less efficiently turned off because of the decrease of GRK-2 activity, one would expect RA patients to be more sensitive to this proinflammatory peptide. The latter may be true in view of enhanced SP signaling during inflammation leading to spinal hyperexcitability, which is responsible for the hyperalgesia characteristic of RA. Another group of important mediators in RA that signal via G-protein-coupled receptors includes the chemokines. In murine models of arthritis, inhibition of chemokine function by specific receptor antagonists for MCP-1 and RANTES can prevent the onset and/or reduce the symptoms once the disease had developed. The monocyte chemoattractant protein-1 MCP-1 is produced at high levels by both infiltrated monocytes and synovial cells in RA (44, 45) , and RANTES and MIP-1␤ (macrophage inflammatory protein-1␤) are more abundantly expressed in both circulating PBL and in synovial fluid T cells of RA patients (46) . It has recently been demonstrated that the MCP-1 chemokine receptor CCR2B is a substrate for GRK-3 and GRK-2 when they are coexpressed in Xenopus oocytes (47) or HEK293 cells (48) , respectively. Moreover, the CCR-5 chemokine receptor, which interacts with MIP-1␤ (macrophage inflammatory protein-1␤) and RANTES, is a substrate for GRK-2 and GRK-3 when overexpressed in HEK-293 cells (49) . Therefore, we suggest that the lower GRK activity will increase the sensitivity for chemokines in cells from RA patients.
In conclusion, although the precise mechanism responsible for the GRK decrease in RA remains to be fully defined, we have shown here that proinflammatory cytokines decrease GRK-2 expression. Moreover, our results suggest that, in RA patients, the proinflammatory signal pathways mediated through some G-protein-coupled receptors (i.e., ␤ 2 -adrenergic, substance P, CCR5) are less efficiently turned off by the GRK/␤-arrestin desensitization machinery. The latter may explain the reported beneficial effects on the onset and the severity of joint injury after treatment with some G-protein-coupled receptor antagonists. Furthermore, these data demonstrates that the GRK/␤-arrestin desensitization machinery can be selectively altered during chronic inflammatory diseases and may open up a field for investigating possible therapeutic strategies, including modulation of GRK activity.
